Physician Payments Sunshine Act Reintroduced for 2009 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Physician Payments Sunshine Act Reintroduced for 2009


ePT--the Electronic Newsletter of Pharmaceutical Technology

Washington, DC (Jan. 22)—Senators Chuck Grassley (R-IA) and Herb Kohl (D-WI) introduced S. 301, known as the Physician Payments Sunshine Act of 2009 to the 111th Congress. The legislation requires drug, device, and medical-supply manufacturers that receive payments through Medicare, Medicaid, or the State Children's Health Insurance Program (SCHIP) to disclose to the US Department of Health and Human Services (HHS) any things of value they give to doctors. Items include payments, gifts, travel compensation, honoraria, and funding for continuing education and research. Companies would be required to report these items beginning Mar. 31, 2011.

The bill also requires HHS to establish procedures for companies to submit the required information and procedures for HHS to make this information available online by Sept. 20, 2011.

The bill amends title XI of the Social Security Act “to provide transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals.” The bill is similar to S. 2029,  which is the 2008 version that was introduced to the 110th Congress but never acted upon. The 2009 legislation clarifies the preemption provisions that were questioned in the previous version. The new bill specifies that states have the authority to collect additional information from companies as long as the information is not specifically covered by federal law.

The bill has been referred to the Senate Committee on Finance.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
11%
All of the above.
39%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here